Comparative Pharmacology
Head-to-head clinical analysis: AMBISOME versus FULVICIN P G 330.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBISOME versus FULVICIN P G 330.
AMBISOME vs FULVICIN P/G 330
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
330 mg orally once daily with fatty meal to enhance absorption.
None Documented
None Documented
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Category C
Category C
Antifungal
Antifungal